TDAC Clears Extension Vote with 95% Approval, 85% of Shares Retained Ahead of Prologium Merger
Translational Development Acquisition Company (NYSE: TDAC) announced June 17, 2026 shareholder vote results showing 95% approval for extending the SPAC's life and 85% of shares not redeemed, preserving $156.8mm in trust for its pending merger with battery maker Prologium.
Translational Development Acquisition Company (NYSE: TDAC) announced shareholder vote results from its June 17, 2026 meeting in which 95% of shares voted approved extending the SPAC's life and 85% of shares were not redeemed, preserving $156.8mm in the trust account.
The extension vote allows TDAC to maintain its capital structure as it moves toward completing the merger with Prologium announced May 27, 2026. Holders of Class A common stock were offered the opportunity to redeem their shares for a pro-rata portion of the trust account in connection with the meeting. The 15% redemption rate left the vehicle with substantially more working capital than many SPAC extensions during this cycle.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.